Is the FDA keeping up with drug approvals amidst COVID-19?

14 May 2020

By Dr Nicola Davies

The global coronavirus pandemic has placed an unprecedented strain on the pharmaceutical industry, with the enforcement of strict lockdown measures disrupting enrolment onto clinical trials and delaying decisions on drugs nearing approval. Understandably, the US Food and Drug Administration is prioritizing the development of an effective coronavirus vaccine and the identification of novel drugs for the treatment of COVID-19. This raises the question of how the approval of non-coronavirus drugs is faring? This is the question that Dr Nicola Davies attempts to answer in her monthly exclusive for The Pharma Letter.

How is COVID-19 affecting FDA drug approvals?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK